Robert Jacobs

Summary

Country: USA

Publications

  1. doi request reprint Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes
    Robert L Jacobs
    Biogenics Research Chamber, San Antonio, TX 78229, USA
    J Allergy Clin Immunol 130:122-7.e8. 2012
  2. doi request reprint Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment
    Robert Jacobs
    Biogenics Research Institute, San Antonio, Texas 78229, USA
    Allergy Asthma Proc 30:120-7. 2009
  3. doi request reprint Validation of the biogenics research chamber for Juniperus ashei (mountain cedar) pollen
    Robert L Jacobs
    Biogenics Research Institute, San Antonio, Texas 78229, USA
    Ann Allergy Asthma Immunol 107:133-8. 2011
  4. doi request reprint Ciclesonide for the treatment of seasonal allergic rhinitis
    Robert L Jacobs
    Biogenics Research Institute and Biogenics Research Chamber, 8229 Fredericksburg Road, San Antonio, TX, USA
    Expert Rev Clin Immunol 7:735-41. 2011
  5. doi request reprint Effectiveness of fluticasone furoate 110 microg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen
    Robert Jacobs
    Biogenics Research Institute, San Antonio, TX 78229, USA
    Curr Med Res Opin 25:1393-401. 2009
  6. doi request reprint Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis
    Paul Ratner
    Sylvana Research Associates, San Antonio, Texas 78229, USA
    Ann Allergy Asthma Immunol 105:471-9. 2010

Detail Information

Publications6

  1. doi request reprint Responses to ragweed pollen in a pollen challenge chamber versus seasonal exposure identify allergic rhinoconjunctivitis endotypes
    Robert L Jacobs
    Biogenics Research Chamber, San Antonio, TX 78229, USA
    J Allergy Clin Immunol 130:122-7.e8. 2012
    ..The level of concordance between allergic symptoms induced on exposure to pollen in a pollen challenge chamber (PCC) versus the natural season is unknown...
  2. doi request reprint Weather/temperature-sensitive vasomotor rhinitis may be refractory to intranasal corticosteroid treatment
    Robert Jacobs
    Biogenics Research Institute, San Antonio, Texas 78229, USA
    Allergy Asthma Proc 30:120-7. 2009
    ..These unexpected results suggest that VMR(w/t) is a distinct subgroup of VMR that is refractory to treatment with INSs. Additional study of other treatments for VMR(w/t) (including INSs) is warranted...
  3. doi request reprint Validation of the biogenics research chamber for Juniperus ashei (mountain cedar) pollen
    Robert L Jacobs
    Biogenics Research Institute, San Antonio, Texas 78229, USA
    Ann Allergy Asthma Immunol 107:133-8. 2011
    ..Pollen challenge chambers have been used to evaluate medication in allergic rhinoconjunctivitis under controlled conditions...
  4. doi request reprint Ciclesonide for the treatment of seasonal allergic rhinitis
    Robert L Jacobs
    Biogenics Research Institute and Biogenics Research Chamber, 8229 Fredericksburg Road, San Antonio, TX, USA
    Expert Rev Clin Immunol 7:735-41. 2011
    ..Ciclesonide is the most recently approved product in this category for the management of seasonal allergic rhinitis and is the subject of this article...
  5. doi request reprint Effectiveness of fluticasone furoate 110 microg once daily in the treatment of nasal and ocular symptoms of seasonal allergic rhinitis in adults and adolescents sensitized to mountain cedar pollen
    Robert Jacobs
    Biogenics Research Institute, San Antonio, TX 78229, USA
    Curr Med Res Opin 25:1393-401. 2009
    ....
  6. doi request reprint Evaluation of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol, 80 or 160 μg once daily, for the treatment of seasonal allergic rhinitis
    Paul Ratner
    Sylvana Research Associates, San Antonio, Texas 78229, USA
    Ann Allergy Asthma Immunol 105:471-9. 2010
    ..A new nasal aerosol formulation of ciclesonide containing a hydrofluoroalkane propellant delivered via a metered-dose inhaler (CIC-HFA) is currently in clinical development as a potential treatment for AR...